LONDON (Alliance News) - Verona Pharma PLC said Monday its recently completed multiple ascending dose study of RPL554 for the treatment of acute exacerbations in chronic obstructive pulmonary disease showed the drug was well tolerated across all dose levels.
The company has begun a new multiple ascending dose study in up to 30 chronic obstructive pulmonary disease patients, where each dose will be given for five consecutive days. This study aims to further confirm the safety and tolerability of the drug, and investigate bronchodilation in these patients. This study makes up the final part of a phase I/II clinical trial with RPL554 using a new nebulised formulation.
Verona Pharma expects results from this final part of the trial in the third quarter of 2015.
By Hana Stewart-Smith; hanassmith@alliancenews.com; @HanaSSAllNews
Copyright 2015 Alliance News Limited. All Rights Reserved.
